Breaking News
April 24, 2018 - Study sheds new light on how bilinguals process language
April 24, 2018 - Probiotics can improve liver health, shows study
April 24, 2018 - Study may explain how chemoresistance evolves over time in some triple-negative breast cancers
April 24, 2018 - Role of midbrain in encoding identity errors
April 23, 2018 - Salamander study provides clues for treating spinal cord injuries
April 23, 2018 - Relaxation after work could give better night’s sleep
April 23, 2018 - Loneliness on its way to becoming Britain’s most lethal condition
April 23, 2018 - Low-cost blood test for multiple myeloma can deliver same diagnostic information as bone biopsy
April 23, 2018 - Metabolic differences may contribute to postpartum weight retention in black moms
April 23, 2018 - Time-Related Deployment Factors Predict Suicide Attempt Risk
April 23, 2018 - Are newborns ugly? Research says newborns rated ‘less cute’ than older babies
April 23, 2018 - Prenatal marijuana use linked to increased chance of low birth weights
April 23, 2018 - Researchers identify target gene in P. aeruginosa infection
April 23, 2018 - New studies related to causes of liver degradation and possible treatments
April 23, 2018 - Studies offer leads for new approaches to treat neurological problems
April 23, 2018 - Gene Therapy May Be Cure for Some With Rare Blood Disorder
April 23, 2018 - Obesity impacts liver health in kids as young as eight years old
April 23, 2018 - Frequent cannabis use by young people linked to small reductions in cognitive function
April 23, 2018 - Innovative research could lead to new ways to treat, prevent cancer
April 23, 2018 - Study uncovers possible source of gender differences in migraines
April 23, 2018 - Study proves usefulness of EDX testing in diagnosis, management of neuromuscular disorders
April 23, 2018 - Hacking ‘drug trafficking’ system could increase effectiveness of diabetes treatment
April 23, 2018 - Clinical trial to examine stem cell therapy for treatment, prevention of complications after traumatic injury
April 23, 2018 - Targeted radiotherapy found to be a good option for women with early breast cancer
April 23, 2018 - Eating fish could prevent Parkinson’s disease
April 23, 2018 - Philips showcases dedicated radiation oncology solutions at ESTRO 2018
April 23, 2018 - Key factor in development of Parkinson’s disease identified
April 23, 2018 - Higher consumption of fish linked to better neurological health
April 23, 2018 - Genevac announces HT Series 3 evaporators with Inert Gas Purge option
April 23, 2018 - Researchers clarify immune response for patients with breast cancer brain metastases
April 23, 2018 - Polypharmacy More Likely for Cancer Survivors
April 23, 2018 - Obesity is shifting cancer to young adults
April 23, 2018 - Scientists illustrate role of novel chromosomal mutations in fosfomycin resistance
April 23, 2018 - Newly developed drug compound may help treat Charcot-Marie-Tooth disease
April 23, 2018 - Marriage Means ‘I Do’ for Skin Cancer Detection
April 23, 2018 - Freezing hunger-signaling nerve may help ignite weight loss
April 23, 2018 - Wear exoskeletons with caution for heavy lifting, researchers say
April 23, 2018 - Research offers new hope for healing wounds in patients with diabetes
April 23, 2018 - Shorter courses of radiotherapy found to be safe, effective for prostate cancer patients
April 23, 2018 - Scientists use CRISPR tool to make multiple edits to DNA samples ‘in vitro’
April 23, 2018 - Knee reconstructions are on the rise among the youth in Australia
April 23, 2018 - Artificial sweeteners linked to obesity warn researchers
April 23, 2018 - CDC seeking $400 million to replace lab for deadliest germs
April 23, 2018 - Sensirion to present single-use liquid flow sensor at COMPAMED 2017
April 23, 2018 - FDA approves contact lenses that shade the sun
April 22, 2018 - Concussion recovery and symptom severity found to vary between men and women
April 22, 2018 - C. Difficile Risk Higher With Stoma Reversal Versus Colectomy
April 22, 2018 - Repeated ranibizumab doesn’t impair macular perfusion
April 22, 2018 - New microscope reveals how cells behave in 3D and real time inside living organisms
April 22, 2018 - Study shows clinical benefit and monetary gains of weight-loss surgery
April 22, 2018 - GNA Biosolutions launches world’s first Laser PCR platform at Medica Trade Fair
April 22, 2018 - Researchers present simulation model to investigate hospital responsiveness to mass casualty incidents
April 22, 2018 - Does Pot Really Dull a Teen’s Brain?
April 22, 2018 - Controversial pregnancy test drug shows deformities in zebrafish embryos within hours of exposure
April 22, 2018 - New research partnership makes childbirth safer in Mozambique
April 22, 2018 - Brief bedside visual art intervention reduces pain, anxiety in cancer patients
April 22, 2018 - The memory part of the brain may also hold clues for anxiety and depression
April 22, 2018 - AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients
April 22, 2018 - New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
April 22, 2018 - Researchers chart a new way to look at concussion
April 22, 2018 - Every parent needs to know fundamental red flags for autism
April 22, 2018 - Anatotemp expands anatomic dental implant healing abutments with 4Side anti-rotational connection
April 22, 2018 - Gene Twist Can Make Your Blood Pressure Spike From Salt
April 22, 2018 - Study suggests failed osteoarthritis drug could help treat opioid addiction
April 22, 2018 - More Americans aware of growing problem of opioid addiction
April 22, 2018 - KHN’s ‘What the Health?’ Nothing in health care ever goes away
April 22, 2018 - BGS to promote high-quality sterilization services at Health GB in Manchester
April 22, 2018 - New integrated POC tool detects biomarkers of heart failure rapidly and precisely
April 22, 2018 - Direct electrical current can be delivered to nerves for blocking pain signals
April 22, 2018 - Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality
April 22, 2018 - Healthy red blood cells owe their shape to muscle-like structures
April 22, 2018 - Researchers present case study of management of rheumatic mitral regurgitation in woman contemplating pregnancy
April 22, 2018 - New black Porvair Krystal UV Quartz microplates for Circular Dichroism measurements
April 22, 2018 - Advanced flow chemistry modules enhance control of nanoprecipitation
April 22, 2018 - Look! Down in the petri dish! It’s a superplatelet!
April 22, 2018 - Research reveals why people with tetraplegia more likely to suffer from sleep apnea
April 21, 2018 - New non-invasive nerve stimulation may offer relief for people with hand tremor
April 21, 2018 - Smartphone App May Up Medication Adherence in HTN
April 21, 2018 - Western diet depletes artery-protecting immune cells
April 21, 2018 - Excelitas Technologies launches new powerful LED light source for fluorescence microscopy
FDA: Many Questions on Novel Opioid Withdrawal Drug

FDA: Many Questions on Novel Opioid Withdrawal Drug

image_pdfDownload PDFimage_print

WASHINGTON — FDA staff expressed numerous concerns about the safety and efficacy of lofexidine, a novel non-opioid drug intended to treat symptoms of opioid withdrawal, in briefing documents prepared for an advisory committee meeting on Tuesday.

Among them: the drug’s trials focused only on short-term use in patients quitting opioids abruptly, raising questions as to whether it would be of any use in other, arguably more common situations including opioid taper.

And the review pointed up several adverse cardiovascular effects seen in the trials, including bradycardia and hypotension.

If approved, lofexidine — developed by Lexington, Ky.-based US WorldMeds with a proposed trade name of Lucemyra — would become the first non-opioid medication approved to treat opioid withdrawal and the first drug approved to help patients successfully terminate their opioid discontinuation treatment.

The Psychopharmacologic Drugs Advisory Committee is scheduled to vote on two overarching questions:

  • Whether “the data provide substantial evidence of effectiveness” for relieving opioid withdrawal symptoms
  • Whether the drug should be approved for this purpose in the context of abrupt opioid discontinuation

The committee is also being asked to discuss the drug’s potential to help patients withdraw completely from opioid dependence, according to the FDA’s meeting materials.

Other topics the committee is schedule to address:

  • Dosing recommendations
  • Whether the available safety data regarding the medication is substantial enough “to support use between 7 and 14 consecutive days”
  • Issues to be addressed in post-marketing studies

Lofexidine is an alpha-2 adrenergic agonist — similar to clonidine, which FDA staff noted is often used off-label for opioid withdrawal symptoms — slated to be part of a long-term treatment plan when patients stop using opioids.

The new medication’s evidence base is limited to two “brief” inpatient studies of OUD patients who suddenly stopped using short-acting opioids, according to the FDA staff review.

US WorldMeds said the studies demonstrate the drug’s ability to reduce opioid withdrawal symptoms in this situation, and that the drug “increases the likelihood that the course of withdrawal treatment will be completed, and the patient will reach a state of no longer being physically dependent.”

“But,” the FDA briefing document noted, “how can we interpret the information on symptomatic relief to determine whether the effect is not just statistically significant, but clinically significant? How do we know if the drug has made enough difference to be clinically meaningful?”

Moreover, the document emphasized that the company’s studies did not directly demonstrate that the symptomatic relief “translates to improvement in completion of detoxification.”

The study data are “very limited” beyond five days of dosing and does not detail the effects of administering the smaller dosages studied in other, older medical literature.

In addition, FDA staff noted that dropout rates in the two studies were very high — well over half by day 7 in the lofexidine groups, although discontinuations were even more common in the placebo groups.

Concerning side effects and adverse events, lofexidine “causes clinically significant hypotension, bradycardia, and orthostatic hypotension in a dose-dependent fashion,” according to the briefing document’s safety summary.

The United Kingdom approved lofexidine in the mid-1980’s to relieve symptoms “in patients undergoing opiate detoxification,” with patients in the 1990’s typically taking doses between 1.6-2.2 mg for a median of 10 days.

The FDA committee is chaired by Rajesh Narendran, MD, a University of Pittsburgh psychiatrist. The FDA is not obliged to follow its advisory committees’ recommendations but it usually does.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles